Starling Oncology Goodwill

The latest goodwill for STLN is $7.2M as of June 2026. That compares with $7.2M in the prior-year period — up 0.0% year over year. Investors often review this figure alongside Starling Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, STLN's goodwill moved from $7.2M to $7.2M — essentially flat versus a year earlier. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Starling Oncology's operating scale or balance-sheet position.

A goodwill figure of $7.2M for STLN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting STLN's goodwill ($7.2M), review year-over-year change from $7.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.